Compare Illumina, Inc. (ILMN) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Kaltura Inc — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while Kaltura Inc trades at $1.63 (market cap $250.18M). The key difference: Illumina, Inc. is far larger — about 115.8× Kaltura Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | KLTR | |
|---|---|---|
Market Cap | $28.96B | $250.18M |
Sector | Health | Technology |
52-Week High | $205.10 | $1.89 |
52-Week Low | $91.00 | $1.08 |
Enterprise Value | $30.32B | $262.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Kaltura (KLTR) trades at $1.75, up 1.74% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue is stable around $181M, but the company remains unprofitable with a net margin of -6.92%. Positive cash flow from operations and industry recognitions for AI and video platforms highlight growth potential, though high debt and insider selling pose concerns.
The outlook is mixed: analyst consensus leans buy (44% buy ratings) on AI innovation and cash flow improvements, but risks include persistent losses, elevated valuation ratios, and competitive pressures. Investors should weigh cost control progress against profitability challenges for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
